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Abstract: Non-coding RNA molecules including microRNAs and long non-coding RNAs (lncRNA) 
have been implicated in the pathogenesis of several tumors and numerous data support their 
applicability in diagnosis as well. Despite recent advances, the pathogenesis of adrenocortical cancer 
still remains elusive and there are no reliable blood-borne markers of adrenocortical malignancy, 
either. Several findings show the potential applicability of microRNAs as biomarkers of malignancy 
and prognosis, and there are some data on lncRNA as well. In this review, we present a synopsis on 
the potential relevance of non-coding RNA molecules in adrenocortical pathogenesis and their 
applicability in diagnosis from tissue and blood. 
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1. Non-Coding RNA Molecules 
Non-coding RNAs (ncRNA) are RNA molecules that do not encode proteins, but participate in 
the regulation or modulation of gene expression, thus they are considered to be parts of the epigenetic 
machinery. Small non-coding RNA molecules (sncRNA) are microRNAs (miRNA), short interfering 
RNAs (siRNA), and PIWI-interacting RNAs (piRNA). Among ncRNAs, miRNA studies are relatively 
abundant in comparison to other subclasses. ncRNAs that are longer than 200 nucleotides are called 
long non-coding RNAs (lncRNA). At least 200,000 unique lncRNAs are described in human tissues 
[1]. They can appear as linear or circular (circRNA) RNA molecules. Linear lncRNAs are important 
regulatory molecules at transcriptional and posttranscriptional levels [2]. circRNAs can act as 
microRNA sponges, thereby holding back miRNAs to bind to mRNAs and initiate degradation [3]. 
Moreover, these RNA molecules are able to regulate transcription and splicing, can inhibit ribosomal 
RNA maturation, and they can function as adaptors in altering protein-protein interaction [4]. 
miRNAs, lncRNAs, and circRNAs have tissue specific appearance and are relatively stable [3,5–7]. In 
this review, we present studies that investigate the role of ncRNAs in adrenocortical cancer 
pathogenesis, diagnosis and therapy. So far, only miRNAs and lncRNAs have been studied in this 
area, hence our review presents these findings. 
  
Cancers 2020, 12, 461 2 of 17 
2. MicroRNAs 
MicroRNAs (miRNA) are short (19–25 nucleotides long) non-coding RNA molecules acting as 
epigenetic regulators of gene expression, mostly at the post-transcriptional level. miRNAs can silence 
messenger RNAs (mRNAs) as the endogenous mediators of RNA interference [8]. miRNAs are 
implicated in the regulation of several physiological and pathological processes including cell cycle, 
cell proliferation, apoptosis, immune regulation, etc. Dysregulation of miRNA expression is 
considered to be an early step of tumor formation [9,10]. miRNAs can function as oncogenes 
(oncogenic miRNAs, oncomiRs) and tumor suppressor miRNAs based on their classical oncogene-
tumor suppressor dichotomy, and this can be related to their relative expression level, as 
overexpressed miRNA are considered to be oncogenic, but are also underexpressed as tumor 
suppressor [11]. 
miRNAs are expressed in a tissue-specific manner. One miRNA can target several different 
mRNAs and several different miRNAs can target a specific mRNA, thus miRNA actions are 
redundant and pleiotropic as well. The expression of miRNAs in tissues can thus be very different. 
A miRNA can have tumor suppressor function in one tissue and function as an oncogene in another 
[11]. 
3. MiRNAs in the Pathogenesis of Adrenocortical Cancer 
Despite recent significant advances in the understanding of adrenocortical cancer (ACC) 
pathogenesis, we are still far from having a clear picture of its development. Several molecular events 
in signaling pathways were shown to have an impact on ACC tumorigenesis [12]. Germline and 
somatic mutations in the TP53 (tumor protein p53) gene [13,14], activation of Wnt/ß-catenin pathway 
through somatic CTNNB1 (catenin beta 1) mutations [15], overexpression of IGF-2 (insulin-like 
growth factor 2) [16,17] and SF1 (steroidogenic factor-1) genes [18], and mutations in mismatch repair 
genes [19] are all related to ACC formation. As miRNAs can target mRNAs, they are also supposed 
to be implicated in the pathogenesis of ACC. In the following, we present the available findings on 
the relevance of miRNAs in ACC pathogenesis. 
3.1. Molecular Pathways Affected by miRNA in ACC 
First, we describe the associations of miRNAs to molecular pathways that are considered to be 
relevant in carcinogenesis, especially in the pathogenesis of ACC (Figure 1). From the previously 
listed genes, only IGF-2 could be linked to miRNA-based regulation in ACC thus far. The IGF-2 gene 
is known to be overexpressed in ACC, and the translated protein binds to the insulin-like growth 
factor 1 receptor (IGF-1R). The activation of this signaling pathway is thought to be relevant in 
adrenocortical tumorigenesis [20]. miR-483-5p and miR-483-3p are miRNAs found to be 
overexpressed in ACC by several studies [21–25]. Their genes are encoded in the intronic region of 
IGF-2 [26]. Simultaneously to IGF-2 overexpression, levels of these miRNAs are also elevated. A 
significant positive correlation can be demonstrated between these two miRNAs and IGF-2 
expression [21,27]. On the other hand, two out of the most down-regulated miRNAs in ACC are miR-
99a and miR-100. These miRNAs can bind to the IGF-1R and mTOR (mammalian target of rapamycin) 
mRNAs thereby regulating the expression of these proteins [28]. However, the underexpression of 
miR-100 could not be correlated with IGF-1R expression in ACC [29]. 
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Figure 1. miRNAs showing oncogenic and tumor suppressor actions in the pathogenesis of ACC by 
targeting mRNAs. Red indicates inhibition, whereas green indicates stimulation. A solid arrow 
indicates a direct relationship, a dotted arrow indicates an indirect relationship. Red letters indicate 
oncogenic function; green letters indicate tumor suppressor function. ACC: adrenocortical cancer; Bcl-
2: B-cell lymphoma 2; IGF-1R: insulin-like growth factor 1—receptor; miR: microRNA; mTOR: 
mammalian target of rapamycin; PUMA: p53 upregulated modulator of apoptosis; ZNF367: zinc 
finger protein 367. 
Silencing miR-483-3p in the hepatocellular carcinoma cell line (HepG2) resulted in decreased cell 
proliferation and increased apoptosis [26]. A similar phenomenon was observed in the human ACC 
cell line (NCI-H295R) as well [22]. miR-483-3p was validated to target the pro-apoptotic PUMA (p53 
upregulated modulator of apoptosis) mRNA, and a significant negative correlation was found 
between the expression of its protein product and miR-483-3p in Wilms’ tumor and other common 
tumors (colon, breast, liver) [26]. miR-483-5p was found to promote cell proliferation in the NCI-
H295R cell line, but in contrast to miR-483-3p, it had no effect on apoptosis (PUMA was not found to 
be a target of miR-483-5p) [22]. 
A number of zinc finger proteins are involved in cancer progression [30]. Zinc finger protein 367 
(ZNF367) is overexpressed in ACC compared to benign adrenal adenomas. This protein was found 
to have effects on cellular adhesion, invasion, migration, and adhesion [31]. It was also demonstrated 
that miR-195 can directly target ZNF367 and thus regulate cellular invasion. A negative correlation 
between the expression of miR-195 and the ZNF367 protein was found [31]. 
Some advanced and poorly differentiated cancers display LIN28A and LIN28B overexpression 
[32,33]. Significant overexpression of LIN28A was observed in ACC relative to adrenocortical 
adenoma (ACA). In aggressive ACC compared to its non-aggressive counterpart, LIN28 protein 
expression was low, but a negative regulator of this protein, miR-9, was overexpressed. This miRNA 
showed strong correlation with survival in ACCs. miR-9 was also overexpressed in ACC compared 
to ACA and normal adrenal cortices [34]. 
The dysregulation of DICER1 that is a principal enzyme in miRNA maturation is also observed 
in a number of various cancers [35,36], while miR-103/miR-107 family has been shown to regulate the 
expression of DICER1 [37]. DICER1 is significantly overexpressed in ACC compared to ACA. Among 
ACC, low expression of DICER1 associated with poor survival and may serve as a prognostic factor 
for local recurrence or metastases. In ACC, miR-107 was overexpressed relative to ACAs [38]. 
3.2. Potential Pathogenic Relevance of miRNA in ACC by High Throughput Techniques 
As a second approach, we present data obtained using high throughput techniques to compare 
the global miRNA expression profiles of ACC and ACA or normal adrenal cortices, in order to find 
differentially expressed miRNAs. MiRNAs showing the largest differences are then subjected to 
target prediction or pathway analysis to identify the most relevant pathomechanisms, and then some 
of these are validated. 
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In our first study on the expression of miRNAs in adrenocortical tumors, we have found 
significantly differentially expressed miRNAs in ACC compared to ACA and normal adrenals 
including overexpressed miR-503, miR-184, miR-210, miR-214, miR-375, and miR-511 in ACC. 
Complex pathway analysis of these miRNAs revealed a cell cycle damage at G2/M checkpoint in 
ACC [39,40]. 
Schmitz et al. identified three significantly down-regulated miRNAs in ACC compared to ACA. 
Pathway analysis of miR-139, miR-675, and miR-335 revealed that miRNAs’ targets include zinc finger 
proteins (Krueppel-related zinc finger protein 4: GLI4 and PR domain zinc finger protein 2: PRDM2) 
[41]. 
Underexpressed miR-205 was found in ACC compared to ACA by Wu et al. Overexpression of 
miR-205 could induce apoptosis, block proliferation in cell culture (SW-13 adrenocortical cancer cell 
line) and also inhibit in vivo tumor growth, suggesting a tumor suppressor role for this miRNA. 
Target prediction revealed Bcl-2 (B-cell lymphoma 2) as a potential target of miR-205. In SW-13 cells, 
a negative correlation between the miRNA and Bcl-2 expression could be observed. miR-205 can 
therefore potentially inhibit tumor progression in ACC via targeting Bcl-2 [42]. 
4. MiRNAs as Potential Biomarkers 
MiRNAs can be exploited as biomarkers since they are expressed in a tissue-specific fashion, 
and their expression is altered due to various diseases, including tumors. Furthermore, miRNAs are 
rather stable, thereby enabling their retrieval from formalin-fixed paraffin-embedded (FFPE) samples 
and also from body fluids. To find miRNA biomarkers, tissue miRNA expression profiles have to be 
compared between diseases (Table 1). Three main discovery methods are used to differentiate 
between groups (polymerase chain reaction (PCR), microarray, and next generation sequencing 
(NGS)). PCR-based and microarray studies can only investigate already known miRNAs, while using 
NGS can also enable previously unknown non-coding miRNAs to be identified. 
Some studies applied snap frozen tissues, while others used formalin-fixed paraffin-embedded 
tissues. miRNA expression in FFPE samples are in correlation with those from snap frozen samples 
[43]. Formalin fixation does not affect the miRNA expression levels, in contrast to those of mRNA 
and DNA [43]. The superiority of any starting material has not been yet determined. 
To correctly compare miRNA expression profiles in samples, pre-analytical variations should be 
considered. To avoid the imprecisions from these variations, normalization or standardization of 
samples is necessary. For this purpose, “housekeeping” RNAs that have similar expression in 
different samples, or externally added controls (like the C. elegans cel-miR-39) are used. A number 
of such molecules have been identified and used so far, but there is no consensus on which reference 
should be used for miRNA studies [44–46]. This represents a major problem with the analysis of 
miRNA expression, especially when body fluids with low miRNA content are used as the source 
material. 
One of the first studies to determine the tissue miRNA expression profile of adrenocortical 
tumors was performed by our research group (Tömböl et al., [39]). Significantly up-regulated (miR-
503, miR-210, and miR-184) and down-regulated (miR-511, miR-214, and miR-375) tissue miRNAs 
were found in ACC compared to ACA samples. The most overexpressed miRNA was miR-503 and 
the most down-regulated was miR-511. When using the difference between these two miRNAs as 
diagnostic marker in the differentiation of ACC and ACA, a sensitivity of 100% and specificity of 97% 
could be achieved (Table 2). This study, however, included only a small number of ACCs (n = 7) [39]. 
In the study of Feinmesser et al., miR-503 was also found to be significantly overexpressed in ACCs 
compared to ACAs, and was found to have perfect diagnostic accuracy, with values of 100% 
sensitivity and specificity [47]. Furthermore, this miRNA might have a prognostic role, as was 
reported by Özata et al., while higher expression of miR-503 was associated with poorer prognosis in 
ACCs [22]. 
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Table 1. Studies on tissue miRNA expression profiling in ACC and ACA. 
Discovery 
Method 







Expression in ACC vs. ACA Reference 
Microarray 22 ACC, 27 ACA, 6 NA RT-qPCR- 9(5) ACA, 10(6) ACC Snap frozen ↓ miR-195, miR-335 [48] 
Microarray 4 ACC, 8 ACA, 4 NA RT-qPCR 
7(3) ACC, 19(11) 
ACA, 10(6) NA 
Snap frozen 
↓ miR-214, miR-511, miR-375;  
↑ miR-503, miR-184, miR-210 
[39] 
Microarray 7 ACC, 9 APA, 4 NA RT-qPCR 15 AT FFPE ↓ miR-139-3p, miR-335, miR-675 [41] 
Microarray 10 ACC, 26 ACA RT-qPCR 29 ACC, 35 ACA Snap frozen 
↓ miR-195, miR-125b, miR-100;  
↑ miR-483-5p 
[21] 
Microarray 22 ACC, 26 ACA, 4 NA RT-qPCR 
25(3) ACC, 43(17) 
ACA, 10(6) NA 
Snap frozen 
↓ miR-1974, miR-195, miR-497;  
↑ miR-483-3p, miR-483-5p, miR-210, miR-21 
[22] 
Microarray 6 ACC, 6 ACA, 6 NA RT-qPCR 
18 ACC, 10 ACA, 3 
NA 
Snap frozen 
↓ miR-335, miR-195;  
↑ miR-139-5p, miR-376a, miR-376b, miR-376c, miR-
483-5p 
[24] 
NGS 45 ACC, 3 NA     Snap frozen 
↓ miR-195, miR-335;  
↑ miR-483-3p, miR-483-5p, miR-210, miR-503 
[25] 
qRT-PCR 51 ACC, 47 ACA     FFPE 
↓ miR-195;  
↑ miR-483-3p, miR-483-5p, miR-210 
[23] 
Microarray 8 ACC, 25 ACA RT-qPCR 11 ACC, 4 ACA,  FFPE 




10 ACC, 26 ACA, 21 
NA 
    Snap frozen 
↑ miR-9, miR-25, miR-124, miR-183, miR-185, miR-
206 
[49] 
NGS 7 ACC, 7 ACA, 8 NA RT-qPCR 8 ACC, 8 ACA, 9 NA FFPE 




10 ACC, 10 ACA, 10 
AML 
RT-qPCR 
12 ACC, 14 ACA, 15 
AML 
FFPE ↑ miR-184, miR-483-5p, miR-483-3p, miR-183-5p [51] 
ACA: adrenocortical adenoma; ACC: adrenocortical carcinoma; AML: adrenal myelolipoma; AT: adrenal tumor; FFPE: formalin-fixed paraffin-embedded; miR: 
microRNA; NGS: next-generation sequencing; NA: normal adrenal; qRT-PCR: quantitative reverse-transcription polymerase chain reaction. 
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Table 2. Diagnostic accuracy of differentially expressed miRNAs in tissue samples. 
miRNA AUC Sensitivity/Specificity Reference 
miR-511 0.985 100%/93% [39] 
Difference of miR-511 and miR-503 0.995 100%/97% [39] 
Difference of miR-511 and miR-184 0.970 100%/80% [39] 
miR-34 and miR-497 n.a. 100%/96%, 100%/89% [47] 
miR-100 0.717 n.a. [21] 
miR-125b 0.763 n.a. [21] 
miR-195 0.771 n.a. [21] 
miR-195 0.830 69%/94% [24] 
miR-210 1.000 n.a. [50] 
miR-335 0.877 88%/88% [24] 
miR-421 0.954 n.a. [50] 
miR-450a-5p 0.974 n.a. [50] 
miR-483-3p 0.987 n.a. [50] 
miR-483-5p 0.943 100%/80% [21] 
miR-483-5p 0.904 74%/100% [24] 
miR-483-5p 1.000 n.a. [50] 
miR-503 n.a. 100%/100% [47] 
miR-503-5p 1.000 n.a. [50] 
Diagnostic accuracy was assessed by receiver operating characteristics (ROC) analysis in most of the 
studies. Available sensitivity and specificity values are presented in the table. AUC: are under curve; 
miR, miRNA: microRNA; n.a.: not available. 
In a larger cohort, Soon et al. have found significantly down-regulated miR-195 and miR-335 in 
ACCs compared to ACAs. miR-7 was found to be significantly underexpressed in both ACA and 
ACC compared to normal adrenals [48]. Another study found miR-139, miR-335, and miR-675 to be 
down-regulated in ACC relative to ACA [41]. Further down-regulated tissue miRNAs in ACC were 
miR-100, miR-125b, and miR-195, while and up-regulated miR-483-5p could discriminate between 
ACC and ACA with a sensitivity and specificity of 80% and 100%, respectively [21]. Özata et al. 
confirmed the up-regulation of miR-483-5p together with miR-483-3p, miR-210, and miR-21 in ACCs. 
miR-210 is considered to be a general hypoxamiR, as its expression is observed in a wide array of 
tumors displaying a hypoxic environment [52]. On the other hand, miR-21 is overexpressed in many 
different tumors, and could be regarded as a wide-spread oncogenic molecule [53]. Unfortunately, 
there are no mechanistic studies yet showing the relevance of miR-210 and miR-21 in ACC 
tumorigenesis. Down-regulation of miR-1974, miR-195, and miR-497 was also observed in ACC 
compared to ACA [22]. Similar observations of differentially expressed miRNAs were done by 
Duregon et al. without validation [23]. miR-335 and miR-195 were significantly underexpressed in 
ACC, while miR-139, miR-376a, -b, -c, and miR-483-5p were significantly up-regulated in ACCs 
compared to ACAs [24]. Assié et al. found down-regulated miR-195 and miR-335, whereas miR-483-
3p, miR-483-5p, miR-210 and miR-503 were up-regulated in ACC compared to normal adrenal cortices. 
These results are not validated in independent cohorts, however, they support former studies [25]. 
An integrated genome-wide analysis has shown that miR-9, miR-25, miR-124, miR-183, miR-185, 
and miR-206 were overexpressed in ACC compared to ACA and were associated with down-
regulated gene expression of at least 10 genes in ACC [49]. 
miRNAs can be useful not only for the differentiation of tumors, but they can also have 
prognostic relevance. miR-483-5p, miR-195, miR-503, miR-1202, and miR-1275 miRNAs were 
significantly associated with poor prognosis of ACC [22,48]. 
In a recent study on tissue miRNA, Koperski et al. found significantly up-regulated miRNAs 
(miR-503-5p, miR-483-3p, miR-483-5p, miR-210, miR-450a, miR-421) that in part corresponded to those 
mentioned previously, in ACC compared to ACA. Diagnostic applicability of significantly 
Cancers 2020, 12, 461 7 of 17 
differentially expressed miRNAs was evaluated by using ROC-analysis. Area under curve was 100% 
only for miR-503-5p, however, the authors have recommended miR-483-3p, miR-483-5p, and miR-210 
in the molecular testing of ACCs, because these miRNAs have had higher mean expression than the 
others [50]. 
Despite many similarities between these different studies, several discrepant results can also be 
observed. Such discrepancies are general features of studies involving miRNA, as no standard 
protocols for sample retrieval, analysis and data interpretation are available yet. This problem is even 
more serious with the study of extracellular miRNA discussed in the next section. 
5. Circulating miRNA as Biomarkers in ACC 
Apart from tissues, miRNAs were also shown to be present in body fluids and thus can be 
exploited as minimally invasive (or even non-invasive) biomarkers. miRNAs are detectable in wide 
range of body fluids including plasma, saliva, tears, urine, amniotic fluid, colostrum, breast milk, 
bronchial lavage, cerebrospinal fluid, peritoneal fluid, pleural fluid, and seminal fluid [54]. The 
blood-derived miRNAs are called circulating miRNAs [55–57]. 
According to our present knowledge, the release of extracellular miRNAs from the parent cell 
can occur in three major ways [58]. Passive release due to cellular damage (necrosis, inflammation), 
or active secretion packed into extracellular vesicles (EV) (microvesicles, exosomes and apoptotic 
bodies) or in association with macromolecular complexes such as Argonaute (AGO) proteins (mainly 
AGO2) and high density lipoprotein (HDL) [59,60]. The vast majority (approximately 90%-95%) of 
the extracellular miRNAs are in complexes with AGO [61,62]. 
Based on novel experimental results, extracellular miRNAs in EVs and associated with HDL 
might be able to get into another cell and alter its gene expression [63,64]. Therefore, circulating 
miRNAs might act as hormone-like molecules by influencing the gene expression, even in distant 
cells or tissues [58,65,66]. In contrast, conflicting results assumed that extracellular miRNAs should 
be regarded as cellular byproducts (debris) lacking biological activity [67,68]. 
There have been eight studies investigating the pattern of extracellular miRNAs in 
adrenocortical tumors (ACT) to date [24,51,69–74] (Table 3). 
All studies confirmed the significant overexpression of miR-483-5p in ACC versus ACA. 
Moreover, Patel et al. found the overrepresentation of miR-34a in ACC samples [69]. On the other 
hand, in the study of Chabre et al., the underrepresentation of miR-195 and miR-335 were confirmed 
in the ACC group [24]. Furthermore, they found a correlation between the expression of miR-483-5p 
and the aggressiveness of ACC. They detected miR-483-5p only in the serum of patients with 
aggressive ACC. Shorter overall and shorter recurrence-free survival were associated with increased 
miR-483-5p and decreased miR-195 expression in the circulation [24]. In our previous study, we found 
significant alteration of blood-borne miRNAs isolated from whole plasma in ACT [70]. Five miRNAs 
(miR-100, miR-181b, miR-184, miR-210, and miR-483-5p) were significantly overexpressed in the 
plasma of patients suffering from ACC versus ACA. In a further study, the absolute plasma level of 
miR-483 and miR-483-5p was measured, and a statistically significant overexpression was identified 
in advanced stages of ACC (stage III-IV) versus to local malignancy (stage I-II), to ACA and to healthy 
patients [71]. Moreover, a correlation between the level of miR-483-5p and the number of circulating 
tumor cells was also revealed. 
According to our current knowledge, there is no unequivocal recommendation whether plasma 
or serum is more appropriate for the evaluation of extracellular miRNAs [56,75]. By applying serum, 
the extracted RNA yield could be higher, but the expression of miRNAs could be affected by the 
coagulation process [76]. In contrast by using plasma, the aforementioned process has no effect, but 
platelet contamination can easily occur [77]. 
Despite the promising results of the above studies, the sensitivity and specificity values of 
miRNA markers were variable. We hypothesized that by studying EV-associated miRNAs, the 
sensitivity and specificity of circulating miRNA could be enhanced. Since the active release of 
miRNAs to EVs seems to be a controlled process, EV-associated miRNAs could be more specific 
markers of malignancy [78]. We therefore investigated the expression of EV-associated miRNAs and 
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their diagnostic applicability and found two miRNAs significantly overexpressed in ACC compared 
to ACA (miR-101 and miR-483-5p) [72]. The diagnostic accuracy of EV-associated miR-483-5p was 
higher than in previous studies on unfractionated plasma or serum (87.5 % and 94.4 %, respectively, 
area under curve: 0,965) [72]. (Table 4) Therefore, EV-associated miR-483-5p appears to be a promising 
minimally invasive biomarker of ACC. The expression of miR-483-5p was not influenced by dynamic 
hormonal tests (low dose overnight dexamethasone and adrenocorticotropin stimulation) used in 
routine hormonal diagnostics that support its utility as a biomarker of ACC [79]. Moreover, 
circulating miR-483-5p could be applied as a marker of treatment efficacy too [80]. The expression of 
miR-483-5p was significantly decreased by a combined therapy (9-cis-retinoic acid and mitotane) in a 
mouse NCI-H295R xenograft model [80]. Regarding another circulating miRNA as a potential marker 
of ACC treatment efficacy, in a SW-13 xenograft model, significant changes in the expression of 
circulating miR-210 (a major hypoxamiR, usually overexpressed under hypoxic conditions 
characteristic for malignant tumors) were noted by liposomal etoposide- doxorubicin-cisplatin-
mitotane combined chemotherapy [81]. We have also found overexpression of circulating miR-210 in 
cortisol-producing ACC [72]. 
In another recent study, we have compared the diagnostic applicability of urinary and whole 
plasma derived miR-483-5p [74]. Significant overexpression of whole plasma miR-483-5p was again 
confirmed in ACC relative to ACA, but although despite being detectable in the urine, no difference 
in urinary miR-483-5p was found between ACA and ACC. 
Despite these promising findings underlining the clinical applicability of miR-483-5p, our recent 
study has revealed a potential limitation [51]. The expression of tissue miRNAs and their circulating 
counterparts were evaluated in patients with adrenal myelolipoma (AML), ACA and ACC, and no 
significant difference was found between the expression of miR-483-3p and miR-483-5p in AML and 
ACC samples that might limit the clinical applicability of miR-483-5p. On the other hand, miR-451a 
could be a promising biomarker for AML. 
We have also studied the expression of circulating miRNAs in hormonally inactive and cortisol-
producing ACTs [73]. miR-22-3p, miR-27a-3p, and miR-320b were significantly overexpressed in both 
cortisol-producing ACA (CPA) and ACC (CP-ACC) compared to non-functioning ACA (NFA). The 
expression of miR-210-3p was significantly increased only in CP-ACC compared to NFA. Moreover, 
significant correlations were revealed between the 24-h urinary free cortisol level and the expression 
of miR-22-3p, miR-27a-3p, and miR-320b. In addition, correlations between the cortisol level after low 
dose dexamethasone test and EV-associated miRNA expression were also established. In our 
previous study, we demonstrated that circulating whole plasma derived miR-27a is influenced by 
dexamethasone and adrenocorticotropin both in vivo and in vitro [79]. In this study, we have 
confirmed that EV-associated miR-27a was also induced by dexamethasone. Based on these results, it 
can be supposed that hypercortisolism might have a role in the overexpression of these miRNAs. 
It must be noted that despite these promising results, there were significant differences in the 
results of studies performed on circulating miRNA. The different methodology, the diversity of the 
reference genes, and the relative low number of patients involved could contribute to this 
discrepancy. Further studies on larger cohorts with uniform methodological requirements are 
warranted to clarify the applicability of circulating miRNA as biomarkers of malignancy, prognosis 
and follow-up. On the other hand, in contrast to their tissue counterparts, there are no data on the 
biological relevance of circulating miRNA in adrenocortical tumors [82,83]. miRNA might work well 
for differentiating two disease entities (e.g., miR-483-5p for differentiating adrenocortical adenoma 
and cancer), but due to their wide-spread expression in other organs, the specificity of miRNA for a 
given disease could be limited. 
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Table 3. Summary of studies reporting circulating miRNA expression findings in adrenocortical cancer. 
Author and Year of 
Publication 
Reference Source Method Samples miRNA Overexpressed in ACC 
miRNA Underexpressed in 
ACC 
Chabre et al. (2013) [24] Serum 
qRT-
PCR 
23 ACC, 4 ACA, 19 NA miR-483-5p miR-195, miR-335 
Patel et al. (2013)  [69] Serum 
qRT-
PCR 
17 ACC, 22 ACA miR-34a, miR-483-5p  
Szabó et al. (2014) [70] Plasma 
qRT-
PCR 
13 ACC, 12 ACA 
miR-100, miR-181b, miR-184, 
miR-210, miR-483-5p 
 





22 ACC, 24 ACA miR-101, miR-483-5p  
Salvianti et al. (2017) [71] Plasma 
qRT-
PCR 
27ACC, 13ACA, 10 NA miR-483-5p  





9 CP-ACC, 13 CPA, 13 
NFA  
miR-22-3p, miR-27a-3p, miR-320b, miR-
210-3p 
 
Decmann et al. (2019)  [74] Plasma  
qRT-
PCR 
23 ACC, 23 ACA miR-483-5p  
Decmann et al. (2018) [51] Plasma 
qRT-
PCR 
11 ACC, 11 ACA, 11 
AML 
miR-483-3p, miR-483-5p   
Abbreviations: ACC: adrenocortical cancer, ACA: adrenocortical adenoma, AML: adrenal myelolipoma, CP-ACC: cortisol-producing ACC, NA: normal adrenal. 
  
Cancers 2020, 12, 461 10 of 17 
Table 4. Diagnostic applicability of extracellular microRNAs for the differentiation of adrenocortical cancer and adrenocortical adenoma. 
Author and Year Reference Comparison miRNA Sensitivity Specificity AUC 
Chabre et al. (2013) [24] ACC-ACA miR-195 90.9 100 0.948 
  aACC-naACC miR-139-5p 87.5 65 0.714 
  ACC-ACA miR-335 95.2 71.4 0.837 
  aACC-naACC miR-376a 71.4 85.7 0.811 
  aACC-naACC miR-483-5p 85.7 100 0.929 
Patel et al. (2013) [69] ACC-ACA miR-34a ND ND 0.81 
  ACC-ACA miR-483-5p ND ND 0.74 
Szabó et al. (2014) [70] ACC-ACA dCTmiR-210 – dCTmiR-181b 88.9 75 0.87 
  ACC-ACA dCTmiR-100/dCTmiR-181b 77.8 100 0.85 
Perge et al. (2017) [72] ACC-ACA miR-483-5p 87.5 94.44 0.965 
  ACC-ACA miR-101 68.75 83.33 0.766 
Salvianti et al. (2017) [71]  miR-483 87.5 63.6 0.875 
   miR-483-5p 83.3 100 0.917 
Perge et al. (2018) [73] CP-ACC-CPA miR-320b 88.89 76.92 0.863 
Decmann et al. (2018) [51] ACC-ACA miR-483-5p 87 78.3 0.88 
Decmann et al. (2019) [74] ACC-ACA miR-483-3p 81.82 90.91 0.88 
Abbreviations: AUC: area under curve, ACC: adrenocortical cancer, aACC: aggressive adrenocortical cancer, naACC: non-aggressive adrenocortical cancer, ACA: 
adrenocortical adenoma, ND: No data, CP-ACC: cortisol-producing ACC, CPA: cortisol-producing ACA.  
.
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6. miRNAs as Potential Therapeutic Mediators or Targets 
miRNAs as major regulators of gene expression are considered to be promising candidates for 
targeted molecular therapies. Soon et al. have shown that miR-7 was significantly down-regulated in 
ACCs compared to normal adrenals [48]. The next study conducted by the same group aimed to find 
a potential miRNA therapeutics for ACC. When reinstating miR-7 expression, it was observed that 
this miRNA negatively affects cell proliferation and induces arrest in the G1 phase of cell cycle in cell 
culture and reduced tumor growth in ACC xenograft mouse model (H295R). The direct targets of 
miR-7 are the MAPK (mitogen-activated protein kinase) and mTOR signaling pathways, which lead 
to inhibition of CDK1 (cyclin dependent kinase 1) [84]. 
In a further study, the expression and targets of miR-483-5p and miR-193-5p were investigated in 
ACC. The expression level of the two miRNAs correlated with the aggressiveness of ACC. The most 
down-regulated potential target gene of miR-483-5p was the N-myc downstream-regulated gene 2 
(NDRG2), whereas the most downregulated target gene for miR-139-5p was NDRG4. The expression 
of these two genes was negatively correlated with the aggressiveness of ACC. Therefore, these genes 
were suggested to be tumor suppressor genes. When the expression of these two miRNAs was 
inhibited in cell lines, the two target genes were overexpressed. The inhibition of miR-483-5p and miR-
139-5p and the restoration of the two genes suppressed the invasive potential of ACC cell lines in 
vitro [85]. 
An additional miRNA, miR-497, was found to be significantly down-regulated in ACC and could 
post-transcriptionally repress the long non-coding RNA (lncRNA) MALAT1. A molecular target of 
miR-497 is the eukaryotic translation initiation factor 4E (iIF4E). MALAT1 also competes for the 
binding site of this miRNA. It was demonstrated that the overexpression of miR-497 and the silencing 
of MALAT1 down-regulates eIF4E, and thus suppress cellular proliferation and induces cell cycle 
arrest [86]. 
7. Long Non-Coding RNA Molecules in ACC 
Long non-coding RNAs (lncRNA) are at least 200 nucleotides long and do not encode proteins 
[87]. lncRNAs are generally stable, but similarly to mRNAs exhibit a broad range of variation in their 
stability profile, making them a dynamic component in response to environmental changes that can 
modulate gene expression. On the other hand, highly stable lncRNAs may play a role in 
housekeeping functions [88,89]. Their stability depends upon their genomic position, subcellular 
localization, RNA binding proteins, splicing, and guanine-cytosine content, but their stability is not 
correlated with their rate of expression [89]. lncRNAs are thought to encompass nearly 30,000 
different transcripts in humans, hence lncRNA transcripts account for the major part of the noncoding 
transcriptome. Long noncoding RNAs play a significant role in carcinogenesis. lncRNAs control 
various biological processes via multiple mechanisms, including guiding epigenetic modifiers and 
transcription factors to their target genes, functioning as sponges for endogenous RNAs, regulating 
mRNA decay, mediating chromosomal interactions, etc. Furthermore, lncRNAs exhibit higher 
specificity in expression profile than mRNAs not only in cell, tissue, and developmental stages, but 
also in a disease state-specific manner [87]. 
In contrast to the several studies on microRNAs conducted in adrenocortical tumors, there has 
only been one study reporting on the expression of long noncoding RNAs (lncRNA) so far [48,90–
92]. This study sheds light on differential expression patterns of lncRNAs in adrenocortical carcinoma 
(ACC), adrenocortical adenoma (ACA), as well as in normal adrenal cortex (NAC) and suggests novel 
prognostic markers and therapeutic targets [93]. 
Both microarray and next generation sequencing are appropriate methods for assessing lncRNA 
expression [94], but there are reports preferring microarray [95]. The study on ACC used a microarray 
platform [93]. 
In the ACC-NAC comparison, 476 lncRNAs were up-regulated and 480 were down-regulated 
in ACC [93]. GAS5 (growth specific arrest 5), a tumorsuppressor lncRNA in breast cancer was also 
found to be downregulated in ACC [96]. Other examples for cancer-related, differentially expressed 
lncRNAs were guanine nucleotide-binding protein, GNAS-AS1 (alpha-stimulating-antisense 1), H19, 
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MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), PRINS (psoriasis-associated 
RNA induced by stress) and maternally expressed 3 (MEG3) [97,98]. 
Regarding the ACA NAC comparison, 1999 lncRNAs were found to be upregulated, whilst 656 
lncRNAs were downregulated in ACC. Interestingly, the cancer-related MALAT1 was one of the 
most upregulated lncRNA [99]. In recurring ACC, only PRINS has been proved to be significantly 
associated with non-recurring ACC, and this lncRNA appears to be a relevant tumor suppressor in 
ACCs [93]. 
Also, PRINS was found to be down-regulated in metastatic ACC. PRINS will be worthy of 
further studies and it might be exploited as a prognostic marker or even as a therapeutic target. 
Despite these findings on the potential tumor suppressor activity of PRINS, its expression could not 
be correlated to overall survival in ACC [93]. 
8. Conclusions 
According to the latest findings, non-coding RNAs are of great importance regarding not only 
in physiological processes, but also in the pathogenesis of various diseases. Both miRNAs and 
lncRNAs are able to function as tumor suppressors or oncogenes, and their aberrant expression can 
lead to tumorigenesis. In the previous two decades, we have learnt a lot about miRNAs. The 
pathogenesis of adrenocortical cancer is still poorly elucidated, and studies on non-coding RNA can 
contribute to its better understanding. A very promising field of ncRNA (mostly miRNA) in ACC is 
related to their use as possible biomarkers not only in tissues, but also as minimally invasive 
biomarkers as a form of liquid biopsy from biofluid samples. Moreover, ncRNAs are also potential 
candidates for genetic therapies in oncological care. 
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